濮阳东方医院男科治疗阳痿技术安全放心濮阳东方医院治阳痿价格非常低,濮阳东方医院在哪里,濮阳东方医院治早泄技术安全放心,濮阳东方医院看妇科病很靠谱,濮阳东方看男科病技术很专业,濮阳市东方医院评价很高,濮阳东方医院男科公交路线

THE HAGUE, June 1(Xinhua) -- Five people in the Netherlands have been sickened with an unusual strain of the E. coli bacteria, the institute for public health (RIVM) reported Wednesday.Of the five patients, four also suffered from intestinal problems and renal failure. The five who are infected all had recently been in Germany.The patients were infected with enterohaemorrhagic E.coli, or EHEC, a particularly deadly strain of the common bacteria found in the digestive systems of cows, humans and other mammals.The outbreak has hit at least eight European countries but virtually all of the sick people either live in Germany or recently traveled there.Medical authorities appeared no closer to discovering either the source of the infection or the mystery at the heart of the outbreak: why the unusual strain of the E. coli bacteria appears to be causing so many cases of hemolytic uremic syndrome, which attacks the kidneys and can cause seizures, strokes and comas.Earlier this week German researchers showed that Dutch cucumbers were not the cause of the contamination."It is essential to quickly find the source, as long as that is not found, the contamination can spread. It's a very aggressive bacteria and many people are seriously ill," a RIVM spokesman said.

BEIJING, July 20 (Xinhuanet) -- Some U.S. soldiers returning from the Middle East have acquired constrictive bronchiolitis, a kind of lung damage virtually unknown in young adults, according to U.S. News & World Report."Respiratory disorders are emerging as a major consequence of service in southwest Asia," said study author Dr. Matthew S. King, an assistant professor of pulmonary and critical care at Meharry Medical College in Nashville, Tenn."In addition to our study, there have been studies showing increases in asthma, obstructive lung disease, allergic rhinitis and a general increase in reports of respiratory symptoms," he added. "Most of the patients say they can’t seem to catch their breath when exerting themselves."On the other hand, Anthony Szema, a physician and engineer at Stony Brook University in New York, has examined a soldier and found tiny complexes of titanium and iron in the man’s lungs, where metals can cause severe damage.Mined separately, the two metals could have gotten together only through a manufacturing process, Szema reported. While the metals’ origin is unclear, he presents a new case study, suspecting garbage-burning pits or exploding devices sent them airborne.While the cases in the study represent only a few dozen people of the hundreds of thousands serving in the Middle East, there is no estimate of how many more might have bronchiolitis.it is recommended that soldiers exercise caution in the field until more is known. Soldiers are now told to wear a mask when burning garbage.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

WASHINGTON, Aug. 2 (Xinhua) -- The weakness of aging is associated with leaky calcium channels inside muscle cells and a drug already in Phase II clinical trials for the treatment of heart failure might plug those leaks, according to a report published Tuesday in the online edition of Cell Metabolism.Earlier studies by the research team led by Andrew Marks of Columbia University showed the same leaks underlie the weakness and fatigue that come with heart failure and Duchenne muscular dystrophy."It's interesting, normal people essentially acquire a form of muscular dystrophy with age," Marks said. "The basis for muscle weakness is the same." Extreme exercise like that done by marathon runners also springs the same sort of leaks, he added, but in that case damaged muscles return to normal after a few days of rest. A microscopic view shows smooth muscle cells derived from human embryonic stem cells showing the nuclei (blue) and proteins of the cytoskeleton (green) in this handout photo released to Reuters by the California Institute for Regenerative Medicine, March 9, 2009The leaks occur in a calcium release channel called ryanodine receptor 1 (RyR1) that is required for muscles to contract. Under conditions of stress, those channels are chemically modified and lose a stabilizing subunit known as calstabin1.Calcium inside of muscle cells is usually kept contained. When it is allowed to leak out into the cell that calcium itself is toxic, turning on an enzyme that chews up muscle cells. Once the leak starts, it's a vicious cycle. The calcium leak raises levels of damaging reactive oxygen species, which oxidize RyR1 and worsen the leak.The researchers made their discovery by studying the skeletal muscles of young and old mice. They also showed that 6-month-old mice carrying a mutation that made their RyR1 channels leaky showed the same muscular defects and weakness characteristic of older mice.When older mice were treated with a drug known as S107, the calcium leak in their muscles slowed and the animals voluntarily showed about a 50 percent increase in the amount of time spent wheel running. Now in clinical trials for patients with heart failure, the drug is known to work by restoring the connection between costabilin and RyR1.Despite considerable effort to understand and reverse age- related muscle wasting, there are no established treatments available. The new work suggests there may be hope in approaching the problem from a different angle."Most research has focused on making more muscle mass," Marks said. "What's different here is that we are focused not on muscle mass but on muscle function. More muscle doesn't help if it is not functional."

BUDAPEST, June 25 (Xinhua) -- Visiting Chinese Premier Wen Jiabao made a five-point proposal here Saturday to enhance China's cooperation with countries in Central and Eastern Europe.When delivering a speech at the China-Central and East European Countries Economic and Trade Forum, Wen said China cherished its longstanding and deep friendship with the countries in the region."Over the past several decades, although the international situation and the domestic situations of both sides have undergone big changes, we have always enjoyed mutual respect, mutual trust, mutual understanding and mutual support," Wen said. Chinese Premier Wen Jiabao addresses the China-Central and Eastern European Countries Economic and Trade Forum in Budapest, Hungary, June 25, 2011.He said cooperation in various fields between the two sides had made tremendous progress, referring to the rapid growth of two-way trade, the burgeoning of mutual investment, the expansion of cooperation areas and the improvement of cooperation mechanisms.China encouraged its companies to "go global" and saw Central and Eastern Europe as a strategic priority, the Chinese leader said, adding that his current visit was "both a journey of friendship and a journey of cooperation."